Trifluoromethylsulfonamide gamma secretase inhibitor
View Patent ↗The present invention is directed to a novel trifluoromethylsulfonamide derivative which inhibits the processing of APP by the putative γ-secretase and thus is useful in the treatment or prevention of Alzheimer's disease. This compound possesses favorable pharmacokinetic properties in higher species (rhesus) and thus can be dosed on an intermittent dosing regiment (e.g., once weekly). When dosed on such a regiment the compound exhibits significant and continuous Aβ lowering without the manifestation of Notch associated gastrointestinal toxicity for extended periods, e.g., 7 days. Pharmaceutical compositions and methods of use are also included.
1. A compound which is
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 which is
or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising a compound according to claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
4. A method for treating a disease involving deposition of β-amyloid (Aβ) in the brain which comprises administering to a human patient in need thereof a compound according to claim 2 or a pharmaceutically acceptable salt thereof by an intermittent dosing regimen, the intermittent dosing regiment comprising repeating cycles of drug administration in which the compound is administered on one or more consecutive days followed by one or more consecutive days of rest on which the compound is not administered.
5. A method for treating Alzheimer's disease in a human patient in need thereof which comprises administering to the patient a compound according to claim 2 or a pharmaceutically acceptable salt thereof by an intermittent dosing regimen, the intermittent dosing regiment comprising repeating cycles of drug administration in which the compound is administered on one or more consecutive days followed by one or more consecutive days of rest on which the compound is not administered.
6. The method according to claim 5 wherein the intermittent dosing regimen comprises a repeating cycle of compound administration on 1 to 3 consecutive days followed by at least 4 days of rest.
7. The method according to claim 5 wherein the compound or pharmaceutically acceptable salt thereof is administered on 3 consecutive days followed by 4 days of rest.
8. The method according to claim 5 wherein the compound or pharmaceutically acceptable salt thereof is administered on 1 day followed by 6 days of rest.